Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/9949
Title: | Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology) | Authors: | Süner, A. Aydin, D. Hacioglu, M.B. Dogu, Gököz Gamze Imamoglu, G.I. Menekşe, S. Pilanci, K.N. |
Keywords: | Cabazitaxel Chemotherapy Prostate cancer Toxicities antiandrogen cabazitaxel docetaxel granulocyte colony stimulating factor prednisolone antineoplastic agent taxoid adult aged anemia anorexia Article cancer center cancer chemotherapy cancer control cancer diagnosis cancer growth cancer patient cancer survival castration resistant prostate cancer controlled study diarrhea disease severity drug dose reduction drug efficacy drug fatality drug safety fatigue febrile neutropenia human human tissue major clinical study male medical society metastasis potential nausea neutropenia orchiectomy overall survival peripheral neuropathy progression free survival prostate adenocarcinoma retrospective study survival time thrombocytopenia treatment response Turk (people) vomiting clinical trial disease free survival epidemiology metastasis middle aged mortality multicenter study pathology Prostatic Neoplasms, Castration-Resistant treatment outcome Turkey very elderly Adult Aged Aged, 80 and over Antineoplastic Agents Disease-Free Survival Humans Male Middle Aged Neoplasm Metastasis Retrospective Studies Taxoids Treatment Outcome |
Publisher: | Verduci Editore | Abstract: | OBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) that progresses after docetaxel. Phase 3 TROPIC study demonstrated that cabazitaxel prolongs survival. PATIENTS AND METHODS: In this study, we evaluated a total of 103 patients who took cabaz-itaxel chemotherapy for mCRPC diagnosis in 21 centers of Turkey, retrospectively. This study included patients who progressed despite doc-etaxel treatments, had ECOG performance score between 0-2, and used cabazitaxel treatment. Patients received cabazitaxel 25 mg/m2 at every 3 weeks, and prednisolone 5 mg twice a day. RESULTS: Median number of cabazitaxel cures was 5.03 (range: 1-17). Cabazitaxel response evaluation detected that 34% of the patients had a partial response, 22.3% had stable disease and 32% had a progressive disease. Grade 3-4 hema-tological toxicities were neutropenia (28.2%), neutropenic fever (14.5%), anemia (6.7%), and thrombocytopenia (3.8%). In our study, median progression-free survival (PFS) was 7.7 months and overall survival (OS) was 10.6 months. CONCLUSIONS: This study reflects toxicity profile of Turkish patients as a Caucasian race. We suggest that cabazitaxel is a safe and effective treatment option for mCRPC patients who progress after docetaxel. Moreover, ethnicity may play important roles both in treatment response and in toxicity profile. | URI: | https://hdl.handle.net/11499/9949 | ISSN: | 1128-3602 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
4
checked on Nov 23, 2024
WEB OF SCIENCETM
Citations
4
checked on Nov 22, 2024
Page view(s)
32
checked on Aug 24, 2024
Google ScholarTM
Check
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.